2 recruiting, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 2, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
Follow DEB-TACE: new trials by email Literature Review of DEB-TACE trials Research Report on DEB-TACE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma DEB-TACE, Toripalimab, Lenvatinib - Liver Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 29 | 2026-06-30 | 2026-07-06 |
| ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC Lenvatinib, Pembrolizumab, Atezolizumab - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 300 | 2025-02-19 | 2025-12-01 |
| DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC DEB-TACE+HAIC, DEB-TACE - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 130 | 2024-05-01 | 2025-02-20 |
| Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma DEB-TACE, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable | Phase 2 | Unknown | Tongji Hospital | 36 | 2023-12-09 | 2024-01-09 |
| Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC Tremelimumab, Durvalumab, Y-90 SIRT - Hepatocellular Carcinoma Non-resectable, HCC | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 55 | 2020-12-15 | 2026-06-23 |
| Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC Sintilimab, DEB-TACE - Hepatocellular Carcinoma | Phase 2 | Unknown | Zhejiang University | 61 | 2019-11-20 | 2022-06-09 |
| Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR) Trans-arterial Chemo-Embolization, Doxorubicin, Stereotactic Ablative Radiotherapy - Liver Neoplasms, Hepatocellular Cancer | Phase 2 | Terminated | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 3 | 2017-02-20 | 2017-11-07 |
Carcinoma, Hepatocellular (4) · Liver Neoplasms (2) · Cholangiocarcinoma (1)
Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Peking Union Medical College Hospital (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · Shanghai Zhongshan Hospital (1) · Tongji Hospital (1) · Zhejiang University (1)
China (4) · Belgium (1) · Germany (1)
Arndt Vogel, Prof. Dr. (1) · Salah-Eddin Al-Batran, Prof. Dr. (1) · Ze-yang Ding, M.D. (1)
2019 (1)